Pfizer: "Children's Antibodies Increase 6-Fold After Booster Shot" FDA Application Soon

[Asia Economy New York=Special Correspondent Joselgina] Pfizer-BioNTech announced on the 14th (local time) that the COVID-19 vaccine booster shot enhances the immune response in children aged 5 to 11.

According to The New York Times (NYT), in a small clinical trial conducted by Pfizer and BioNTech involving 140 children aged 5 to 11, the antibody levels against COVID-19 one month after receiving the booster shot increased sixfold compared to one month after the second dose.

Laboratory tests on blood samples from a subgroup of 30 children showed that antibody levels in those who received the booster shot were 36 times higher than those who only received the second dose one month later.

This announcement came amid a rise in COVID-19 cases in the United States due to the spread of the BA.2 subvariant of Omicron. The two companies plan to apply to the U.S. Food and Drug Administration (FDA) within days to approve the COVID-19 vaccine booster shot for children aged 5 to 11. Currently, booster shots are only available for those aged 12 and older in the United States.

This content was produced with the assistance of AI translation services.